West Pharmaceutical Services, Inc.

NYSE:WST

Medical - Instruments & Supplies

Healthcare
$404.02 +1.56%

+$5.04 today

Market cap
$28.14B
Beta
1.18
P/E (TTM)
43.6
EPS (TTM)
$7.54
Dividend yield
0.26%
52W Low $206.80High $336.82

Volume 0.59M

Average 0.85M

WST EBITDA Margin

EBITDA as a percentage of revenue.

West Pharmaceutical Services, Inc.NYSE: WST

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin holds steady near 25.8%

EBITDA Margin was 25.8% in Q2 FY2026, down 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 26.2%, up 0.5 pp year over year. Over 3 fiscal years it narrowed by 2.9 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 30.1% for the fiscal year ending Dec 2026, up from 25.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
25.8%-0.0 pp QoQ
Last fiscal yearDec 2025
25.1%-0.6 pp YoY
LTMJun 2026
26.2%+0.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.1 pp+1.3 pp+1.3 pp
1 year-0.6 pp+5.0 pp+5.7 pp
3 years-2.9 pp+7.7 pp+10.7 pp
5 years+11.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
25.1%
Year-over-year change
-0.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How WST compares with its peers on the latest reported figures

  • WST's LTM Jun 2026 EBITDA Margin of 26.2% is the highest of the 5 companies compared; the peer median is 16.2%.
  • Its year-over-year change of +0.5 pp is the highest of 5, against a peer median of -2.5 pp.
  • Over three fiscal years its change of -2.9 pp compares with a peer median of +4.6 pp.
WST Competitors Peer median
EBITDA Margin for WST and competitors
Company Period LTM level YoY 3-year change
WSTWest Pharmaceutical Services, Inc.LTM Jun 202626.2% +0.5 pp-2.9 pp
STVNStevanato Group S.p.A.LTM Jun 202624.3% -2.8 pp-0.4 pp
ATRAptarGroup, Inc.LTM Jun 202620.9% -1.5 pp+3.7 pp
ICUIICU Medical, Inc.LTM Jun 202611.5% -2.1 pp+5.5 pp
BLFSBioLife Solutions, Inc.LTM Mar 2026-7.5% -19.9 pp+166.6 pp
Peer median (excluding WST) 16.2%-2.5 pp+4.6 pp

Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.83B2.89B2.95B2.89B3.07B
Cost of Revenue1.66B1.75B1.82B1.89B1.97B
Gross Profit1.17B1.14B1.13B1B1.1B
Gross Margin41.5%39.5%38.4%34.6%35.9%
Research & Development52.8M58.5M68.4M69.1M74.3M
Selling, General & Admin361.9M316.9M353.4M338.5M393.1M
Operating Expenses414.7M375.4M421.8M407.6M485.9M
Depreciation & Amortization122.3M120.6M137.3M155.4M171.4M
EBITDA879.7M808.1M844.1M743.8M770.6M
EBITDA Margin31.1%28.0%28.6%25.7%25.1%
Operating Income758.7M763.5M710.9M594.6M617.4M
Operating Margin26.8%26.5%24.1%20.6%20.1%
Interest Income1M5.1M28M19.6M17.7M
Interest Expense8.5M7.6M8.8M2.9M600K
Other Income / Expenses10.3M(62.9M)4.8M5.6M(2.1M)
Income Before Tax769M700.6M715.7M600.2M615.3M
Pre-Tax Margin27.2%24.3%24.3%20.7%20.0%
Income Tax Expense107.2M114.7M122.3M107.5M121.6M
Net Income661.8M585.9M593.4M492.7M493.7M
Net Margin23.4%20.3%20.1%17.0%16.1%
EPS (Basic)8.907.887.996.756.83
EPS (Diluted)8.677.737.886.696.80
Weighted Avg Shares74.4M74.4M74.3M73M72.3M
Weighted Avg Shares (Diluted)76.3M75.8M75.3M73.7M72.7M

West Pharmaceutical Services, Inc.

NYSE:WST

Intrinsic Alpha fair value

Locked

Current Price

$404.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.